Presentation Authors: BOB YANG*, Claire Foley, Steve Foley, READING, United Kingdom
Introduction: UTIs are prevalent worldwide, with incidence increasing with age. Lower oestrogen levels post-menopause leads to the loss of the acidic vaginal defence, thus increasing risks of UTIs. These women often require long-term antibiotics. _x000D_
However the alarming rise of antibiotic resistance worldwide, along with a WHO Global Action Plan combating resistance, provides an urgent need to find viable alternatives._x000D_
FemTouch is a thermo-ablative laser which induces a histological rejuvenation of the vaginal lining, with thickened squamous epithelium, glycogen storage and extracellular matrix synthesis, similar to oestrogen therapy._x000D_
We present the first experience in the United Kingdom of using FemTouch to treat a preliminary cohort of postmenopausal women with recurrent UTIs.
Methods: 12 post-menopausal women with recurrent UTIs received 3 courses of FemTouch treatment at monthly intervals. Prior to treatment, all women underwent a cervical smear for cytology and MC&S._x000D_
Subsequent follow-up for up to 12 months post first treatment assessed rates of UTI, changes in vaginal pH and vaginal health._x000D_
No concurrent antibiotic or hormonal therapy was used throughout.
Results: 9/12 (75%) of women were UTI free in the 12 months follow up. 1 patient had first recurrence at 6 months. 2 further patients had UTI recurrences at month 9._x000D_
Vaginal acidity improved from pH 7.0 pretreatment to pH 5.4 at 6 months, rising to pH 6.2 by 12 months._x000D_
Vaginal Health Index Score showed improvement from 11 (â‰¤15 is deemed atrophic) pre-treatment to 20 at 3 months and 19 at 6 months. By 12 months this had decreased to 15._x000D_
All patients completed treatment and described the &[Prime]pain&[Prime] of the procedure as 1/10 on average.
Conclusions: These initial results suggest that FemTouch is both effective and safe in postmenopausal women with recurrent UTIs and may be a potentially viable alternative to antibiotic prophylaxis. _x000D_
FemTouch also greatly restored vaginal conditions out of the atrophic state._x000D_
The positive benefits with FemTouch treatment appears to start wearing off by 12 months, suggesting a further course may be needed on a yearly basis._x000D_
Our preliminary results supports creating an international multi-centre trial to further investigate FemTouch in larger groups of patients with longer follow-up periods.